Find Out if You Qualify for a Financial Reward by filling out the form below.
Investigation Details
On July 24, 2024, after the market closed, MaxLinear announced earnings results for its second quarter of 2024 and that net revenue for the quarter was just $92 million, down 50% year-over-year. The company attributed the decline at least in part to prolonged burn-off of excess customer inventory leading to weakened demand. The news caused a precipitous decline in the price of MaxLinear stock. The price of the company’s stock closed at $22.29 per share on July 24, 2024. Prior to the market open, MaxLinear stock declined 26% on July 25, 2024.
| Ticker Symbol | Company Name | Join Deadline | Join |
|---|---|---|---|
| APLT | Applied Therapeutics, Inc. | February 18, 2025 | Join |
| BIOA | BioAge Labs, Inc. | March 10, 2025 | Join |
| PCRX | Pacira BioSciences, Inc. | March 14, 2025 | Join |
| NVO | Novo Nordisk A/S | March 25, 2025 | Join |
| GO | Grocery Outlet Holding Corp. | March 31, 2025 | Join |
| NEM | Newmont Corporation | April 01, 2025 | Join |
| GSK | GSK plc | April 07, 2025 | Join |
| NTLA | Intellia Therapeutics, Inc. | April 14, 2025 | Join |
| MRK | Merck & Co., Inc. | April 14, 2025 | Join |